Thromboembolism - Pipeline Review, H1 2019

Thromboembolism - Pipeline Review, H1 2019

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Thromboembolism - Pipeline Review, H1 2019, provides an overview of the Thromboembolism (Cardiovascular) pipeline landscape.

When a blood clot (thrombus) breaks and travels in the blood, this is called a thromboembolism. Symptoms include warmth, edema, and erythema, and may also include dilated veins (collaterals) on the chest wall or leg. Risk factors include hypertension, diabetes mellitus, cigarette smoking, and high cholesterol levels. Treatment includes anticoagulants, thrombolytic therapy and surgery.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Thromboembolism - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Thromboembolism (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thromboembolism (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Thromboembolism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 3, 1, 2, 7, 1 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Thromboembolism (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Thromboembolism (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Thromboembolism (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Thromboembolism (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Thromboembolism (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Thromboembolism (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Thromboembolism (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Thromboembolism (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Thromboembolism - Overview
Thromboembolism - Therapeutics Development
Thromboembolism - Therapeutics Assessment
Thromboembolism - Companies Involved in Therapeutics Development
Thromboembolism - Drug Profiles
Thromboembolism - Dormant Projects
Thromboembolism - Discontinued Products
Thromboembolism - Product Development Milestones
Appendix

List Of Tables


Number of Products under Development for Thromboembolism, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Universities/Institutes, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Thromboembolism - Pipeline by Accu-Break Pharmaceuticals Inc, H1 2019
Thromboembolism - Pipeline by Bayer AG, H1 2019
Thromboembolism - Pipeline by China Biologic Products Inc, H1 2019
Thromboembolism - Pipeline by Daiichi Sankyo Co Ltd, H1 2019
Thromboembolism - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2019
Thromboembolism - Pipeline by F. Hoffmann-La Roche Ltd, H1 2019
Thromboembolism - Pipeline by GC Pharma, H1 2019
Thromboembolism - Pipeline by Ionis Pharmaceuticals Inc, H1 2019
Thromboembolism - Pipeline by Johnson & Johnson, H1 2019
Thromboembolism - Pipeline by Laboratorios Farmaceuticos Rovi SA, H1 2019
Thromboembolism - Pipeline by Portola Pharmaceuticals Inc, H1 2019
Thromboembolism - Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2019
Thromboembolism - Pipeline by Tetherex Pharmaceuticals Corp, H1 2019
Thromboembolism - Pipeline by Verseon Corp, H1 2019
Thromboembolism - Dormant Projects, H1 2019
Thromboembolism - Dormant Projects, H1 2019 (Contd..1), H1 2019
Thromboembolism - Discontinued Products, H1 2019

List Of Figures


Number of Products under Development for Thromboembolism, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products by Top 10 Targets, H1 2019
Number of Products by Stage and Top 10 Targets, H1 2019
Number of Products by Top 10 Mechanism of Actions, H1 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Top 10 Molecule Types, H1 2019
Number of Products by Stage and Top 10 Molecule Types, H1 2019

Venous Thromboembolism (Cardiovascular) - Drugs in Development, 2021

Venous Thromboembolism (Cardiovascular) - Drugs in Development, 2021Venous Thromboembolism (Cardiovascular) - Drugs in Development, 2021 provides an overview of the Venous Thromboembolism pipeline landscape.The report provides comprehensive information on the

USD 2000 View Report

Venous Thromboembolism - Market Insight, Epidemiology and Market Forecast - 2028

Venous Thromboembolism - Market Insight, Epidemiology and Market Forecast - 2028 report provides a detailed analysis of the Venous Thromboembolism epidemiology and market outlook for the 7MM.Markets

USD 6250 View Report

Natural Killer Cell Therapies - Pipeline Insight, 2021

DelveInsights, Natural Killer Cell Therapies - Pipeline Insight, 2021, report provides comprehensive insights about 100+ companies and 140+ pipeline drugs in Natural Killer Cell Therapies pipeline landscape. It covers the

USD 3000 View Report

Binge-eating disorder - Pipeline Insight, 2021

DelveInsights, Binge-eating disorder - Pipeline Insight, 2021, report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Binge-eating disorder pipeline landscape. It covers the pipeline drug profiles, including

USD 1500 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available